Shares of Charles River Laboratories International Inc. (NYSE:CRL) have been given a consensus rating of “Hold” by the thirteen ratings firms that are currently covering the firm. Two equities research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $85.45.

Several research firms have recently commented on CRL. Zacks Investment Research cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, November 4th. Credit Suisse Group AG reaffirmed a “neutral” rating on shares of Charles River Laboratories International in a research report on Friday, September 30th. Evercore ISI reaffirmed a “hold” rating and issued a $91.50 target price (up from $83.50) on shares of Charles River Laboratories International in a research report on Thursday, August 4th. Jefferies Group raised their target price on shares of Charles River Laboratories International from $94.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, August 4th. Finally, Citigroup Inc. raised their target price on shares of Charles River Laboratories International from $85.00 to $90.00 and gave the stock a “neutral” rating in a research report on Thursday, August 4th.

Charles River Laboratories International (NYSE:CRL) opened at 74.63 on Friday. The company’s 50-day moving average is $79.04 and its 200 day moving average is $82.38. The stock has a market capitalization of $3.53 billion, a PE ratio of 25.22 and a beta of 1.18. Charles River Laboratories International has a 12-month low of $65.70 and a 12-month high of $89.18.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 2nd. The company reported $1.18 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.13 by $0.05. Charles River Laboratories International had a net margin of 9.05% and a return on equity of 25.11%. The firm earned $425.70 million during the quarter, compared to analysts’ expectations of $291.20 million. During the same period last year, the company posted $1.03 EPS. The company’s quarterly revenue was up 21.8% compared to the same quarter last year. On average, equities research analysts expect that Charles River Laboratories International will post $4.47 earnings per share for the current fiscal year.

In other Charles River Laboratories International news, insider Davide Molho sold 7,877 shares of the firm’s stock in a transaction dated Tuesday, August 30th. The shares were sold at an average price of $84.10, for a total transaction of $662,455.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 2.30% of the company’s stock.

Several hedge funds have recently made changes to their positions in CRL. Quantbot Technologies LP increased its stake in shares of Charles River Laboratories International by 291.7% in the third quarter. Quantbot Technologies LP now owns 1,414 shares of the company’s stock worth $117,000 after buying an additional 1,053 shares during the last quarter. BlackRock Japan Co. Ltd increased its stake in shares of Charles River Laboratories International by 55.9% in the second quarter. BlackRock Japan Co. Ltd now owns 1,640 shares of the company’s stock worth $135,000 after buying an additional 588 shares during the last quarter. Tower Research Capital LLC TRC bought a new stake in shares of Charles River Laboratories International during the third quarter worth about $181,000. MAI Capital Management bought a new stake in shares of Charles River Laboratories International during the third quarter worth about $209,000. Finally, Laurion Capital Management LP bought a new stake in shares of Charles River Laboratories International during the second quarter worth about $209,000. 97.12% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

5 Day Chart for NYSE:CRL

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.